24Jul/13

Harbour Antibodies Licenses H2L2 Mice to Pfizer – MarketWatch

Harbour Antibodies Licenses H2L2 Mice to Pfizer
MarketWatch
ROTTERDAM, the Netherlands & CAMBRIDGE, Mass., Jul 24, 2013 (BUSINESS WIRE) — Harbour Antibodies, the creator of transgenic mice to aid in the development of new human therapeutic antibodies, announced today that it has licensed its H2L2 mice, 
Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development PharmiWeb.com (press release)
Atlas leads €2.5m round for Harbour Antibodiesunquote news (subscription)
Pfizer licenses antibody tech from Atlas-backed startup HarbourFierceBiotech

all 4 news articles »

24Jul/13

Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Merck … – HispanicBusiness.com

Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Merck
HispanicBusiness.com
monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab

and more »